logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 7 of 7 Items
Showing 1 - 7 of 7 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Immunogenicity of an extended dose interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen in adults and children in the Democratic Republic of the Congo

Choi EM, Kasonia K, Kavunga-Membo H, Mukadi-Bamuleka D, Soumah A,  et al.
2024-07-26 • Vaccines
2024-07-26 • Vaccines

During the 2018–2020 Ebola virus disease outbreak in Democratic Republic of the Congo, a phase 3 trial of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine (DRC-EB-001) commenced in Goma, wit...

Journal Article
|
Research

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

Sissoko D, Laouenan C, Folkesson E, M’Lebing A, Beavogui A,  et al.
2016-03-01 • PLOS Medicine
2016-03-01 • PLOS Medicine
Ebola virus disease (EVD) is a highly lethal condition for which no specific treatment has proven efficacy. In September 2014, while the Ebola outbreak was at its peak, the World Health ...
Journal Article
|
Research

Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea

Boum Y II, Juan-Giner A, Hitchings MD, Soumah A, Strecker T,  et al.
2020-06-01 • Vaccine
2020-06-01 • Vaccine
Background
As part of a Phase III trial with the Ebola vaccine rVSVΔG-ZEBOV-GP in Guinea, we invited frontline workers (FLWs) to participate in a sub-study to provide additional inf...
Journal Article
|
Research

Factors influencing participation in an Ebola vaccine trial among frontline workers in Guinea

Grantz KH, Claudot P, Kambala M, Kouyate M, Soumah A,  et al.
2019-11-15 • Vaccine
2019-11-15 • Vaccine
BACKGROUND
Alongside the clinical aspects of the immunogenicity and safety trial of an Ebola vaccine deployed among front-line workers, a qualitative study was conducted to describe ...
Journal Article
|
Research

Factors influencing participation in an Ebola vaccine trial among front-line workers in Guinea

Grantz KH, Claudot P, Kambala M, Kouyate M, Soumah A,  et al.
2019-11-15 • Vaccine
2019-11-15 • Vaccine
BACKGROUND
Alongside the clinical aspects of the immunogenicity and safety trial of an Ebola vaccine deployed among front-line workers, a qualitative study was conducted to describe ...
Journal Article
|
Research

Efficacy and Effectiveness of an rVSV-Vectored Vaccine in Preventing Ebola Virus Disease: Final Results from the Guinea Ring Vaccination, Open-Label, Cluster-Randomised Trial (Ebola Ça Suffit!)

Henao-Restrepo AM, Camacho A, Longini I, Watson CH, Edmunds WJ,  et al.
2017-02-01 • Lancet
2017-02-01 • Lancet
BACKGROUND
rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested the ...
Journal Article
|
Research

Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea

Juan-Giner A, Tchaton M, Jemmy J-P, Soumah A, Boum Y II,  et al.
2018-09-25 • Vaccine
2018-09-25 • Vaccine
As part of the ring vaccination trial in Guinea, Front Line Workers were invited to participate in a sub-study to provide additional information on the immunogenicity and safety of rVSVΔ...